1 / 21

Innovative Pharmaceutical Solutions for Health and Safety

During the course of this presentation for Laniprin Life Sciences Inc., it is possible that statements in regard to a number of matters may constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. This presentation includes various statement

savannah
Download Presentation

Innovative Pharmaceutical Solutions for Health and Safety

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Innovative Pharmaceutical Solutions for Health and Safety Confidential and Proprietary For others, no logo on building.For others, no logo on building.

    2. During the course of this presentation for Laniprin Life Sciences Inc., it is possible that statements in regard to a number of matters may constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. This presentation includes various statements that may, from time to time, differ substantially from those anticipated in any statements made today. The statements made within reflect the current views of the Laniprin Life Sciences Inc. management team and may be amended in future documentation or filings. The statements contained within this presentation may include risks and uncertainties that products in the development stage, may not achieve scientific objectives, regulatory requirements, market acceptance of the products in development, impact of competitive products and/or pricing. Confidential and Proprietary

    3. Mission Statement Laniprin envisions becoming a world leader in serving pain management product needs of health providers and consumers. It will do so by combining patented and proprietary biopharmaceutical technologies it controls with existing products to create new proprietary products that will have distinct advantages over existing products in the marketplace.

    4. Confidential and Proprietary

    5. Picture of pills?Picture of pills?

    6. Product Pipeline Overview

    7. Long Acting Aspirin Reduces the number of pills taken on a daily basis; facilitates adherence to treatment regimens. Minimizes the risk of developing ulcers or hemorrhage. The delivery system contains no harmful additives. Low dosage (81 mg) aspirin for treatment and prevention of cardiovascular disease. High dosage one-a-day for treatment of arthritic pain.

    8. OTC Rx Industry Statistics THE FACTS: Aspirin is the most consumed drug worldwide. Each year 50 billion tablets are ingested (30 billion in the US alone) Cardiovascular disease is the leading cause of death worldwide, accounting for approximately one third of all deaths. Aspirin’s most popular use is heart disease prevention (37.6%) - Laniprin 81 mg. product. Total pain remedies sales, US market $3.2B (source: AC Nielsen, compiled April 2001)

    9. Comparable Analysis

    10. Comparable Analysis

    11. Acetaminophen Another one of the Company’s products in our pipeline is a long acting, taste enhanced, children’s Acetaminophen. Benefits: Avoids unnecessary interruption of a child’s sleep, school or daily activities in order to administer desirable doses. Cost Effective. Slow release molecule provides safety and efficacy.

    12. Laniprin plans to introduce a controlled release one-a-day Ibuprofen for the following benefits: Controls pain and inflammation in patients with rheumatoid arthritis and osteoarthritis. Benefits similar to the Laniprin controlled-release aspirin.

    13. Laniprin’s Analgesic Premedicated Patch Mask and Device Transdermal Technology The inventor of two therapeutic medical devices, both of which have been patented by the United States Patent Office. The first one, Patent # 5700238, is a device and method for treatment of headache. The second, Patent # 6313370, is a medicated wrap.

    16. Patented Medicated Wrap A device for treating pain in an injured body member, includes a wrap having an interior section, for the insertion of analgesic formulation. Includes at least one inwardly extending module adapted to exert pressure on and compress a specific area of the injured member, having acupressure-like effect and producing pain relief. Can be used in conjunction with any of the many already FDA-approved medications and patches.

    17. Executive Management Team

    19. Marketing and Sales The Rogich Communications Group, a leading international public relations firm, will provide public, financial, media, and government relations services to Laniprin Life Sciences, Inc. Affinity Products will be the contract partner for marketing, distribution, and sales functions for US launch of Laniprin’s products. Key members of management will lead a marketing and sales effort that is planned with and implemented by established pharmaceutical marketing and sales organizations. Management of product development is tied to marketing strategy for timely manufacture and effective product launch. All contract manufacturers will meet FDA or other relevant governmental requirements. Initial launch will reach 20,000 retail drug stores in the United States and will expand to 50,000 within one year.

    20. Product Time Line

More Related